Reshape the Fates of Treg and CD8+T Cells Through IL‐2Rα by Synergizing Divergent Receptor‐Biased IL‐2 PEGylates

Abstract Clinical trials of receptor‐biased interleukin‐2 (IL‐2) variants in cancer therapy show limited efficacy. To investigate, we re‐evaluated divergent receptor‐biased IL‐2 PEGylates (generated via site‐specific PEGylation at residues D20 (not‐β) and Y45 (not‐α)), alone or in combination. Resul...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jiaqi Sun, Lingfeng Guo, Dezhong Ji, Mengfan Yu, Boyang Cheng, Xingxing Zhu, Yeshuang Yuan, Siyu Wu, Yuanjie Zhang, Wen Shi, Zhiqian Chen, Xindang Chu, Jiayu Hu, Liwen Hua, Yiming Wang, Yanning Zhu, Yu Mu, Hanwen Sun, Chuanling Zhang, Qi Wang, Sulong Xiao, Lihe Zhang, Bo Zhang, Demin Zhou
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-05-01
Series:	Advanced Science
Assuntos:	CD8+ T interleukin‐2 PEGylation tumor immunotharapy
Acceso en liña:	https://doi.org/10.1002/advs.202414931
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!